Buy Vesilute Research Peptide

What is Vesilute?

Vesilute is a peptide bioregulator from the Russian program, designed to target liver and bile-system tissue. It is studied in animal research for its effects on liver-cell signaling in the context of aging.

• A short peptide studied for its effects on liver and bile-system tissue
• Part of the Russian organ-targeted bioregulator research program
• Studied in animal research for its effects on liver-cell gene activity
• Investigated alongside other organ-specific bioregulators from the same program

For research use only. Not approved for human therapeutic use.

Vesilute is a synthetic dipeptide bioregulator with a molecular weight of 262.2 g/mol. Developed at the Saint Petersburg Institute of Bioregulation and Gerontology as part of the Khavinson peptide bioregulator series, Vesilute was designed based on peptide fractions associated with urinary bladder and vesical tissue. As one of the shortest peptides in the Khavinson bioregulator catalogue, it represents the minimal dipeptide unit investigated for organ-specific gene expression modulation within this research framework. Like other Khavinson bioregulators, Vesilute is proposed to exert its biological activity through direct interaction with DNA rather than cell surface receptor-mediated signalling. Produced via solid-phase peptide synthesis, Vesilute is associated with bladder tissue gene expression and urogenital signalling pathways.

Vesilute is an organ-specific dipeptide bioregulator targeting vesical tissue within the Khavinson framework. Its proposed mode of action is a defining, experimentally documented property of the Khavinson ultrashort-peptide class: fluorescently labelled short peptides of this family penetrate into the cell nucleus and bind genomic DNA in a sequence-selective manner, providing a structural basis for peptide-directed modulation of gene activity [1], and this direct-to-DNA principle of short-peptide control over tissue-specific gene expression has since been consolidated in a systematic review of the field [2]. Within that framework, Vesilute is studied as a vesical-tropic geroprotector under the tissue-specific bioregulator concept, in which organ-derived short peptides are investigated for the capacity to counteract age-associated changes in their target tissue [3], making Vesilute a reference compound in preclinical bioregulation research examining vesical tissue specificity, short-peptide/DNA interaction models, and age-associated regulation of organ-specific gene expression.

Vesilute is produced to research-grade standards and independently verified by third-party HPLC and MS-UPLC analysis before dispatch. Vials are vacuum sealed and stored in a temperature controlled, monitored cold storage system. Certificates of Analysis are available on request.

Sold strictly for in vitro research purposes only. Not for human consumption. Intended for use by qualified researchers in laboratory settings only.

References

1Fedoreyeva LI, Kireev II, Khavinson VK, Vanyushin BF. Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Mosc). 2011 Nov;76(11):1210–9. .PubMed PMID: 221175472Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021 Nov 22;26(22):7053. ; PubMed Central PMCID: PMC8619776.PubMed PMID: 348341473Khavinson VK. Peptides and Ageing. Neuro Endocrinol Lett. 2002;23 Suppl 3:11–144. .PubMed PMID: 12374906

Scientific Review

Dr. Martina Rossi, PhD

Scientific Contributor and Reviewer

Reviewed for scientific accuracy, 14 June 2026

View credentials →

Vesilute is a synthetic dipeptide bioregulator with a molecular weight of 262.2 g/mol. Developed at the Saint Petersburg Institute of Bioregulation and Gerontology as part of the Khavinson peptide bioregulator series, Vesilute was designed based on peptide fractions associated with urinary bladder and vesical tissue. As one of the shortest peptides in the Khavinson bioregulator catalogue, it represents the minimal dipeptide unit investigated for organ-specific gene expression modulation within this research framework. Like other Khavinson bioregulators, Vesilute is proposed to exert its biological activity through direct interaction with DNA rather than cell surface receptor-mediated signalling. Produced via solid-phase peptide synthesis, Vesilute is associated with bladder tissue gene expression and urogenital signalling pathways.

Vesilute is an organ-specific dipeptide bioregulator targeting vesical tissue within the Khavinson framework. Its proposed mode of action is a defining, experimentally documented property of the Khavinson ultrashort-peptide class: fluorescently labelled short peptides of this family penetrate into the cell nucleus and bind genomic DNA in a sequence-selective manner, providing a structural basis for peptide-directed modulation of gene activity [1], and this direct-to-DNA principle of short-peptide control over tissue-specific gene expression has since been consolidated in a systematic review of the field [2]. Within that framework, Vesilute is studied as a vesical-tropic geroprotector under the tissue-specific bioregulator concept, in which organ-derived short peptides are investigated for the capacity to counteract age-associated changes in their target tissue [3], making Vesilute a reference compound in preclinical bioregulation research examining vesical tissue specificity, short-peptide/DNA interaction models, and age-associated regulation of organ-specific gene expression.

Vesilute is produced to research-grade standards and independently verified by third-party HPLC and MS-UPLC analysis before dispatch. Vials are vacuum sealed and stored in a temperature controlled, monitored cold storage system. Certificates of Analysis are available on request.

Sold strictly for in vitro research purposes only. Not for human consumption. Intended for use by qualified researchers in laboratory settings only.

References

1Fedoreyeva LI, Kireev II, Khavinson VK, Vanyushin BF. Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Mosc). 2011 Nov;76(11):1210–9. .PubMed PMID: 221175472Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021 Nov 22;26(22):7053. ; PubMed Central PMCID: PMC8619776.PubMed PMID: 348341473Khavinson VK. Peptides and Ageing. Neuro Endocrinol Lett. 2002;23 Suppl 3:11–144. .PubMed PMID: 12374906

Scientific Review

Dr. Martina Rossi, PhD

Scientific Contributor and Reviewer

Reviewed for scientific accuracy, 14 June 2026

View credentials →CAS NumberN/A (Khavinson bioregulator)Molecular Weight262.22 g/molPurity≥98%Physical FormLyophilised PowderManufacturingManufactured in an ISO9001 Certified LaboratoryTestingHPLC + MS-UPLCSKURSC-VESILUTE-4110

Lyophilised powder: store at -20 °C or below, away from light and moisture. Once reconstituted in an appropriate laboratory diluent (e.g. sterile water, PBS, or assay buffer), store at 2–8 °C and use within the validated period for your protocol. Do not refreeze.

Vesilute is a synthetic dipeptide bioregulator with a molecular weight of 262.2 g/mol. Developed at the Saint Petersburg Institute of Bioregulation and Gerontology as part of the Khavinson peptide bioregulator series, Vesilute was designed based on peptide fractions associated with urinary bladder and vesical tissue. As one of the shortest peptides in the Khavinson bioregulator catalogue, it represents the minimal dipeptide unit investigated for organ-specific gene expression modulation within this research framework. Like other Khavinson bioregulators, Vesilute is proposed to exert its biological activity through direct interaction with DNA rather than cell surface receptor-mediated signalling. Produced via solid-phase peptide synthesis, Vesilute is associated with bladder tissue gene expression and urogenital signalling pathways.

Vesilute is an organ-specific dipeptide bioregulator targeting vesical tissue within the Khavinson framework. Its proposed mode of action is a defining, experimentally documented property of the Khavinson ultrashort-peptide class: fluorescently labelled short peptides of this family penetrate into the cell nucleus and bind genomic DNA in a sequence-selective manner, providing a structural basis for peptide-directed modulation of gene activity [1], and this direct-to-DNA principle of short-peptide control over tissue-specific gene expression has since been consolidated in a systematic review of the field [2]. Within that framework, Vesilute is studied as a vesical-tropic geroprotector under the tissue-specific bioregulator concept, in which organ-derived short peptides are investigated for the capacity to counteract age-associated changes in their target tissue [3], making Vesilute a reference compound in preclinical bioregulation research examining vesical tissue specificity, short-peptide/DNA interaction models, and age-associated regulation of organ-specific gene expression.

Vesilute is produced to research-grade standards and independently verified by third-party HPLC and MS-UPLC analysis before dispatch. Vials are vacuum sealed and stored in a temperature controlled, monitored cold storage system. Certificates of Analysis are available on request.

Sold strictly for in vitro research purposes only. Not for human consumption. Intended for use by qualified researchers in laboratory settings only.

References

1Fedoreyeva LI, Kireev II, Khavinson VK, Vanyushin BF. Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Mosc). 2011 Nov;76(11):1210–9. .PubMed PMID: 221175472Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021 Nov 22;26(22):7053. ; PubMed Central PMCID: PMC8619776.PubMed PMID: 348341473Khavinson VK. Peptides and Ageing. Neuro Endocrinol Lett. 2002;23 Suppl 3:11–144. .PubMed PMID: 12374906

Scientific Review

Dr. Martina Rossi, PhD

Scientific Contributor and Reviewer

Reviewed for scientific accuracy, 14 June 2026

View credentials →CAS NumberN/A (Khavinson bioregulator)Molecular Weight262.22 g/molPurity≥98%Physical FormLyophilised PowderManufacturingManufactured in an ISO9001 Certified LaboratoryTestingHPLC + MS-UPLCSKURSC-VESILUTE-4110

Lyophilised powder: store at -20 °C or below, away from light and moisture. Once reconstituted in an appropriate laboratory diluent (e.g. sterile water, PBS, or assay buffer), store at 2–8 °C and use within the validated period for your protocol. Do not refreeze.